USANA Health Sciences’ Twiggs Money Flow is rocketing higher on the launch of two new products in Canada.
USANA has launched Prenatal CellSentials® and MagneCal D™ products in Canada. The Prenatal CellSentials is a comprehensive vitamin supplement for pregnant women and their developing babies that provides high-quality vitamins and minerals to help support a healthy pregnancy. MagneCal D is an all-encompassing bone-health supplement that combines optimal amounts of magnesium, calcium and vitamin D to help individuals maintain a strong, healthy body.
USANA Health Sciences Stock Chart
The Twiggs Money Flow has exploded higher which suggests the stock is being accumulated. The Effective Volume study shows large players volume is slowly rising which is bullish.
We first added USANA Health Sciences to our watch list back on September 13, 2017 here. Should traders take a new position in USANA Health? Probably not. Price movement has been a little bit too volatile to find a good entry and exit point. It is probably a good idea to wait for a consolidation first.
USANA Health Sciences Review
USANA Health Sciences (USNA) Return On Asserts of 18.41% is among the best returns of the industry. USNA outperforms 96% of its industry peers. The industry average Return On Assets is -41.76%. USNA has a Profit Margin of 9.47%. This is better than the industry average of -46.01%. USNA's Return On Equity of 25.21% is inline with the rest of the industry. The industry average Return On Equity is 30.94%. The Piotroski-F score of USNA is 6.00. This is a neutral score and indicates average health and profitability for USNA.
With a Price/Earnings Ratio of 15, USNA is valued correctly. Compared to an average industry Price/Earning Ratio of 22.7, USNA is valued inline with its industry peers. With a Forward Price/Earnings Ratio of 13.3, USNA is valued correctly. USNA's PEG Ratio of 1.5 which compensates the Price/Earnings for growth, indicates a correct valuation of the company. With a price book ratio of 3.69, USNA is valued correctly. Compared to an average industry price book ratio of 3.95, USNA is valued inline with its industry peers.
Measured over the past 5 years, USNA shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.65% on average per year. The Earnings Per Share has been growing slightly by 1.58% over the past year. Looking at the last year, USNA shows a small growth in Revenue. The Revenue has grown by 5.67% in the last year. Measured over the past 5 years, USNA shows a small growth in Revenue. The Revenue has been growing by 9.46% on average per year.
A Current Ratio of 2.44 indicates that USNA has no problem at all paying its short term obligations. An Altman-Z score of 10.05 indicates that USNA is not in any danger for bankruptcy at the moment. When comparing the Altman-Z score to an average industry Current Ratio of 1.47, USNA is in better financial health than the average industry peer. A Quick Ratio of 1.93 indicates that USNA should not have too much problems paying its short term obligations. The Piotroski-F score of USNA is 6.00. This is a neutral score and indicates average health and profitability for USNA. When comparing the Current Ratio of USNA to the average industry Current Ratio of 4.65, USNA is less able to pay its short term obligations than its industry peers. Compared to an average industry Quick Ratio of 4.42, USNA is worse placed to pay its short term obligations than its industry peers. When comparing the Debt to Equity Ratio of USNA to the average industry Debt to Equity Ratio of 0.00, USNA required more debt to finance its operations than its industry peers.
Latest posts by Lance Jepsen
- YUM Brands Stock Retracement To Previous Resistance Setup - November 20, 2017
- Sarepta Therapeutics In Strong Uptrend From Exondys 51 - November 19, 2017
- Top 16 Companies With Earnings and Revenue Beats - November 19, 2017